Decidual stromal cell therapy for generalized lymphadenopathy as a special clinical manifestation of COVID‐19 infection: A case report |
| |
| Authors: | Ali Pirsalehi Masoud Soleimani Abbas Hajifathali Behnam Sadeghi Behrouz Farhadihosseinabadi Sedigheh Sadat Akhlaghi Elham Roshandel |
| |
| Institution: | 1. Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran Iran ; 2. Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran Iran ; 3. Translational Cell Therapy Research (TCR), Department of Clinical Science, Intervention and Technology, CLINTEC, Karolinska Instituted, Huddinge Sweden |
| |
| Abstract: | We are going through the greatest global health crisis of the last decades, the coronavirus disease 2019 (COVID‐19) pandemic. It may cause morbidity and mortality in some cases, and there is no therapeutic approach with reproducible and favorable outcomes. As clinical manifestations differ from patient to patient, any report regarding clinical symptoms has been beneficial for early detection and treatment. Due to the immunomodulatory effect of mesenchymal stem cells (MSCs), MSCs‐based therapy has been approved to be one of the therapeutic strategies for COVID‐19 management. For the first time in the literature, we reported generalized lymphadenopathy with fever and no sign of respiratory distress in a 16‐year‐old patient with confirmed COVID‐19 infection as the main clinical signs. We also introduce decidual stromal cells as a potential immunomodulatory treatment for COVID‐19–infected patients. |
| |
| Keywords: | COVID‐ 19 COVID‐ 19 cell therapy decidual stromal cell generalized lymphadenopathy |
|
|
